Form 8-K
8-K — Indaptus Therapeutics, Inc.
Accession: 0001493152-26-045040
Filed: 2026-09-30
Period: 2026-09-29
CIK: 0001857044
SIC: 2834 (PHARMACEUTICAL PREPARATIONS)
Item: Entry into a Material Definitive Agreement
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-10.1 (ex10-1.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001857044
0001857044
2026-09-29
2026-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 29, 2026
INDAPTUS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
001-40652
86-3158720
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
3 Columbus
Circle 15th Floor
New
York, New York
10019
(Address of principal executive
offices)
(Zip Code)
(646)
427-2727
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol
Name
of each exchange on which registered
Common Stock, $0.01 par
value
INDP
Nasdaq Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
As
previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. (the “Company”)
with the Securities and Exchange Commission on September 9, 2026 (the “Prior Form 8-K”), on September 8, 2026,
the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with the purchasers party thereto
(collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers,
in a private placement, shares of the Company’s common stock, par value $0.01 per share, for aggregate gross proceeds of approximately
$24.0 million, before deducting offering expenses.
Pursuant
to the Purchase Agreement, the closing of the transactions contemplated thereby was required to occur no later than September 29, 2026
(the “Outside Date”).
On
September 29, 2026, the Company and the Purchasers entered into notices and consents (the “Notices and Consents”)
pursuant to which, among other things, the Outside Date applicable to each Purchaser was extended from September 29, 2026 to October
16, 2026 (the “Extended Outside Date”). The Notices and Consents also permit the Company to defer and coordinate
the closing with respect to the Purchasers until the applicable conditions to closing under the Purchase Agreement have been satisfied
or waived, but in no event later than the Extended Outside Date, unless otherwise agreed in writing by the Company and the applicable
Purchaser. In addition, the deadline for the Purchasers to fund their respective purchase prices under the Purchase Agreement, as well
as certain related termination rights, was extended to the Extended Outside Date.
Except
as modified by the Notices and Consents, the Purchase Agreement remains unchanged and in full force and effect.
The
foregoing description of the Purchase Agreement and the Notices and Consents does not purport to be complete and is qualified in its
entirety by reference to the Purchase Agreement, which was filed as Exhibit 10.1 to the Prior Form 8-K and is incorporated herein by
reference, and the form of the Notice of Extension of Outside Date and Consent to Deferred Closing, which is filed as Exhibit 10.1 to
this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
10.1
Notice of Extension of Outside Date and Consent to Deferred Closing, dated September 29, 2026
104
Cover Page Interactive Data File (embedded within the
Inline XBRL document)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
September 30, 2026
INDAPTUS
THERAPEUTICS, INC.
By:
/s/
Junyi Dai
Name:
Junyi Dai
Title:
Chief Executive Officer
EX-10.1
EX-10.1
Filename: ex10-1.htm · Sequence: 2
Exhibit 10.1
FORM
OF NOTICE OF EXTENSION OF OUTSIDE DATE AND CONSENT TO DEFERRED CLOSING
Date:
September 29, 2026
To:
Reference
is made to that certain Stock Purchase Agreement, dated September 8, 2026 (the “Agreement”), by and between Indaptus Therapeutics,
Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature page(s) thereto (each, a “Purchaser”
and collectively, the “Purchasers”). Capitalized terms used but not otherwise defined herein shall have the meanings set
forth in the Agreement. The Company and the undersigned Purchaser hereby agree, solely as between the Company and such Purchaser, as
follows:
1.
Extension of Outside Date. Notwithstanding anything to the contrary in Section 3.1 of the Agreement, the Outside Date applicable
to the undersigned Purchaser shall be extended from September 29, 2026 to October 16, 2026 (the “Extended Outside
Date”). All references in the Agreement to the “Outside Date,” solely with respect to the undersigned Purchaser,
shall be deemed to refer to the Extended Outside Date.
2.
Deferred and Coordinated Closing. Notwithstanding anything to the contrary in Sections 3.1 or 3.2 of the Agreement, the Closing
with respect to the undersigned Purchaser may be deferred until the Company has received the Subscription Amounts from the
Purchasers participating in the coordinated Closing and the applicable conditions set forth in Section 7 of the Agreement have been
satisfied or waived in accordance with the terms thereof. The Closing with respect to the undersigned Purchaser shall take place on
such date and at such time as may be designated by the Company by written notice to the undersigned Purchaser, but in any event not
later than the Extended Outside Date, unless otherwise agreed in writing by the Company and the undersigned Purchaser.
3.
Previously Delivered Subscription Amounts. If all or any portion of the Subscription Amount of the undersigned Purchaser has
been received by the Company prior to the Closing, the undersigned Purchaser hereby consents to the Company retaining such amount
pending the Closing and agrees that the Company shall not be obligated to issue or deliver the Shares to be purchased by such
Purchaser until the Closing. Such deferral, solely to the extent contemplated hereby, shall not constitute a breach or default by
the Company under the Agreement.
4.
Funding Deadline and Termination Rights. Notwithstanding anything to the contrary in Section 3.2 of the Agreement, the deadline
for the Company to receive the entire Subscription Amount from the undersigned Purchaser shall be extended to the Extended Outside
Date, and the Company shall not exercise its termination right under Section 3.2 solely as a result of the failure of such Purchaser
to deliver its entire Subscription Amount on or before September 29, 2026. For purposes of Section 3.1 of the Agreement, the sixty
(60) day period following the Outside Date shall commence following the Extended Outside Date.
5.
No Default; Continuing Effect. The failure to consummate the Closing with respect to the undersigned Purchaser on or before
September 29, 2026 shall not, solely as a result of the extension contemplated hereby, constitute a breach or default under the
Agreement. Except as expressly modified hereby with respect to the undersigned Purchaser, the Agreement shall remain unchanged and
in full force and effect. In the event of any conflict between the terms of this Notice and Consent and the Agreement, the terms of
this Notice and Consent shall control solely with respect to the undersigned Purchaser.
6.
No Other Amendments. Unless expressly amended by this Notice and Consent , the terms and provisions of the Agreement shall
remain in full force and effect.
7.
Conflicting Terms. Wherever the terms and conditions of this Notice and Consent and the terms and conditions of the Agreement
are in conflict, the terms of this Notice and Consent shall be deemed to supersede the conflicting terms of the
Agreement.
8.
Governing Law. This Notice and Consent shall be governed by, and construed and enforced in accordance with, the Laws of the State
of New York without regard to the choice of law principles thereof.
This
Notice and Consent constitutes a written amendment and consent with respect to the undersigned Purchaser and may be executed in counterparts,
each of which shall be an original, and all of which together shall constitute one instrument.
[Signatures
on Following Page]
SIGNATURE
PAGE
IN
WITNESS WHEREOF, the parties hereto have executed this Notice of Extension of Outside Date and Consent to Deferred Closing as of the
date first above written.
INDAPTUS THERAPEUTICS, INC.
By:
Name:
Title:
By:
Name:
Title:
Date:
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 7
v3.26.3
Cover
Sep. 29, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Sep. 29, 2026
Entity File Number
001-40652
Entity Registrant Name
INDAPTUS
THERAPEUTICS, INC.
Entity Central Index Key
0001857044
Entity Tax Identification Number
86-3158720
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
3 Columbus
Circle 15th Floor
Entity Address, City or Town
New
York
Entity Address, State or Province
NY
Entity Address, Postal Zip Code
10019
City Area Code
(646)
Local Phone Number
427-2727
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, $0.01 par
value
Trading Symbol
INDP
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration